 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Course Introduction and Fundamentals

What Is This Course About?

SLIDE 2 — Concept Simplified

Practical Application and Case Studies

SLIDE 3 — Case Study

SLIDE 4 — Practical Application

Compliance, Risks, and Best Practices

Risk Indicators

PART 4 — 10-Point Audit / Inspection-Readiness Checklist

Quiz

Survey/Feedback

Course Feedback Survey

Welcome to the definitive guide on "Degradant Specification Listing and Acceptance Criteria per ICH Q3B(R2). " Navigating the complex regulatory landscape of pharmaceutical drug product specifications can be challenging, but mastering the ICH Q3B(R2) guidelines is essential for ensuring product quality, safety, and compliance.

Welcome to the definitive guide on "Degradant Specification Listing and Acceptance Criteria per ICH Q3B(R2)." Navigating the complex regulatory landscape of pharmaceutical drug product specifications can be challenging, but mastering the ICH Q3B(R2) guidelines is essential for ensuring product quality, safety, and compliance. This comprehensive course is designed to demystify the fundamental concepts, purpose, and scope of specification listing and acceptance criteria for degradation products. Throughout this training, you will explore the critical differences between ICH Q3B(R2) for drug products and ICH Q3A for drug substances. We will break down key terminology, such as specified versus unspecified and identified versus unidentified degradation products, ensuring you have a rock-solid foundation. Moving beyond theory, the course dives deep into practical applications and real-world case studies. You will learn how to apply the threshold ladder—reporting, identification, and qualification—based on maximum daily dose, and how to formulate appropriate acceptance criteria using data from commercial batches and stability studies. Finally, we will equip you with a robust 10-Point Audit and Inspection-Readiness Checklist, helping you identify risk indicators, avoid common compliance pitfalls, and sustain continuous manufacturing improvement. Whether you are dealing with a new degradant appearing late in a stability study or establishing limits for unspecified impurities, this course provides the step-by-step workflow and data-driven strategies you need to succeed. Enroll today to safeguard patient safety and elevate your CMC compliance expertise!

122. Degradant Specification Listing and Acceptance Criteria per ICH Q3B(R2)

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>Establishing robust drug product specifications is a critical regulatory requirement that directly impacts patient safety, product efficacy, and overall quality assurance. The ICH Q3B(R2) guideline provides the definitive framework for the reporting, identification, and qualification of degradation products in new drug products. Navigating these requirements demands a precise understanding of how threshold ladders scale proportionally with maximum daily doses, as well as the ability to accurately differentiate between specified, unspecified, identified, and unidentified degradants. For quality control analysts, quality assurance reviewers, and regulatory CMC professionals, mastering these concepts is essential to ensure that stability protocols, analytical methods, and release specifications remain strictly compliant with global regulatory expectations.</p>

<p>This comprehensive curriculum systematically explores the principles and practical applications of degradant specification listing and acceptance criteria. The program begins by establishing foundational terminology and delineating the critical differences between drug product degradant guidelines (ICH Q3B) and drug substance impurity guidelines (ICH Q3A). Participants will subsequently engage with real-world case studies, learning to apply threshold logic to complex stability data and formulate appropriate acceptance criteria synthesized from commercial-process batches. Furthermore, the course addresses critical compliance risks, identifies common warning signs in specification documentation, and provides a rigorous 10-point audit-readiness checklist. By integrating analytical method capabilities with stringent regulatory requirements, professionals will be fully equipped to execute data-driven, risk-based decisions that protect patient safety and ensure continuous inspection readiness.</p>
        </div>
    </div>
</div>
